|
1
|
Fuller GN and Scheithauer BW: The 2007
Revised World Health Organization (WHO) Classification of Tumours
of the Central Nervous System: Newly codified entities. Brain
Pathol. 17:304–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS Statistical Report: Primary brain and central nervous system
tumors diagnosed in the United States in 2008–2012. Neuro-oncol. 17
Suppl 4:iv1–iv62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee I: Advances in surgical approaches in
glioblastoma (GBM). Linchuang Zhongliuxue Zazhi. 6:422017.
|
|
4
|
Sanai N, Polley MY, McDermott MW, Parsa AT
and Berger MS: An extent of resection threshold for newly diagnosed
glioblastomas. J Neurosurg. 115:3–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lacroix M, Abi-Said D, Fourney DR,
Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch
SJ, Holland E, et al: A multivariate analysis of 416 patients with
glioblastoma multiforme: Prognosis, extent of resection, and
survival. J Neurosurg. 95:190–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hou J, Deng Q, Zhou J, Zou J, Zhang Y, Tan
P, Zhang W and Cui H: CSN6 controls the proliferation and
metastasis of glioblastoma by CHIP-mediated degradation of EGFR.
Oncogene. 36:1134–1144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lipinski M, Parks DR, Rouse RV and
Herzenberg LA: Human trophoblast cell-surface antigens defined by
monoclonal antibodies. Proc Natl Acad Sci USA. 78:5147–5150. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang
YL, Jou YS, Hong TM and Yang PC: TROP2 is epigenetically
inactivated and modulates IGF-1R signalling in lung adenocarcinoma.
EMBO Mol Med. 4:472–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ripani E, Sacchetti A, Corda D and Alberti
S: Human Trop-2 is a tumor-associated calcium signal transducer.
Int J Cancer. 76:671–676. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shvartsur A and Bonavida B: Trop2 and its
overexpression in cancers: Regulation and clinical/therapeutic
implications. Genes Cancer. 6:84–105. 2015.PubMed/NCBI
|
|
12
|
Cubas R, Li M, Chen C and Yao Q: Trop2: A
possible therapeutic target for late stage epithelial carcinomas.
Biochim Biophys Acta. 1796:309–314. 2009.PubMed/NCBI
|
|
13
|
Ohmachi T, Tanaka F, Mimori K, Inoue H,
Yanaga K and Mori M: Clinical significance of TROP2 expression in
colorectal cancer. Clin Cancer Res. 12:3057–3063. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng Z and Dong XJ: Clinical value of
serum trophoblast cell surface protein 2 (TROP2) antibody in
non-small-cell lung cancer patients. Biomarkers. 21:1–4. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ning S, Liang N, Liu B, Chen X, Pang Q and
Xin T: TROP2 expression and its correlation with tumor
proliferation and angiogenesis in human gliomas. Neurol Sci.
34:1745–1750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao W, Zhu H, Zhang S, Yong H, Wang W,
Zhou Y, Wang B, Wen J, Qiu Z, Ding G, et al: Trop2 is overexpressed
in gastric cancer and predicts poor prognosis. Oncotarget.
7:6136–6145. 2016.PubMed/NCBI
|
|
17
|
Liu X, Li S and Yi F: Trop2 gene: A novel
target for cervical cancer treatment. J Cancer Res Clin Oncol.
140:1331–1341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Son S, Shin S, Rao NV, Um W, Jeon J, Ko H,
Deepagan VG, Kwon S, Lee JY and Park JH: Anti-Trop2
antibody-conjugated bioreducible nanoparticles for targeted triple
negative breast cancer therapy. Int J Biol Macromol. 110:406–415.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao Y, Wang X, Zheng F, Wang C, Tang Q,
Tang X, Xu N, Zhang H, Zhang D, Xiong L, et al: The
tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate
in pancreatic cancer. Oncotarget. 7:24810–24823. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang Q, Bournazou E, Sansone P, Berishaj
M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al:
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and
metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kanda N, Seno H, Konda Y, Marusawa H,
Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y,
et al: STAT3 is constitutively activated and supports cell survival
in association with survivin expression in gastric cancer cells.
Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hajimoradi M, Mohammad Hassan Z, Ebrahimi
M, Soleimani M, Bakhshi M, Firouzi J and Samani FS: STAT3 is
overactivated in gastric cancer stem-like cells. Cell J.
17:617–628. 2016.PubMed/NCBI
|
|
24
|
Rokavec M, Öner MG, Li H, Jackstadt R,
Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, et
al: Corrigendum. IL-6R/STAT3/miR-34a feedback loop promotes
EMT-mediated colorectal cancer invasion and metastasis. J Clin
Invest. 125:13622015. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung SS, Giehl N, Wu Y and Vadgama JV:
STAT3 activation in HER2-overexpressing breast cancer promotes
epithelial-mesenchymal transition and cancer stem cell traits. Int
J Oncol. 44:403–411. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cutolo M and Meroni M: Clinical utility of
the oral JAK inhibitor tofacitinib in the treatment of rheumatoid
arthritis. J Inflamm Res. 6:129–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vyas D, O'Dell KM, Bandy JL and Boyce EG:
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the
treatment of rheumatoid arthritis. Ann Pharmacother. 47:1524–1531.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hashizume M, Tan SL, Takano J, Ohsawa K,
Hasada I, Hanasaki A, Ito I, Mihara M and Nishida K: Tocilizumab, a
humanized anti-IL-6R antibody, as an emerging therapeutic option
for rheumatoid arthritis: Molecular and cellular mechanistic
insights. Int Rev Immunol. 34:265–279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang D, Wang F, Pang Y, Zhao E, Zhu S,
Chen F and Cui H: ALG2 regulates glioblastoma cell proliferation,
migration and tumorigenicity. Biochem Biophys Res Commun.
486:300–306. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang MY, Xuan F, Liu W and Cui HJ: MINA
controls proliferation and tumorigenesis of glioblastoma by
epigenetically regulating cyclins and CDKs via H3K9me3
demethylation. Oncogene. 36:387–396. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group: Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Yuan H, Li Y and Han Y: The role
of HER3 in gastric cancer. Biomed Pharmacother. 68:809–812. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smith J: Erlotinib: Small-molecule
targeted therapy in the treatment of non-small-cell lung cancer.
Clin Ther. 27:1513–1534. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu P, Zhao Y, Liu K, Lin S, Liu X, Wang M,
Yang P, Tian T, Zhu YY and Dai Z: Prognostic role and clinical
significance of trophoblast cell surface antigen 2 in various
carcinomas. Cancer Manag Res. 9:821–837. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guerra E, Trerotola M, Aloisi AL, Tripaldi
R, Vacca G, La Sorda R, Lattanzio R, Piantelli M and Alberti S: The
Trop-2 signalling network in cancer growth. Oncogene. 32:1594–1600.
2013. View Article : Google Scholar : PubMed/NCBI
|
